Price Chart

Executive Summary

CLSA issued a new coverage initiation on ADBE with an Outperform rating and a $300 price target, implying 26.5% upside from the current $237.25. The firm joins a consensus that is tilted toward the sidelines — 17 Buy ratings (52% of 33 analysts) vs. 25 Hold and 3 Sell. CLSA's $300 target is above the mean consensus of $272.48 and the median of $250. The firm carries a 50% accuracy rate on its 16 rated calls with an average return of +17.7%, suggesting above-average stock-picking on the names it covers. Over the past 30 days, ADBE has seen 2 upgrades and 0 downgrades, while EPS estimates for the current and next fiscal years have been revised upward across 25+ analysts. Insider activity shows a mixed signal: a $1.9M buy by officer David Ricks in late June contrasts with CEO Shantanu Narayen's $18.3M in sales in April. A congressional buy by Rep. Ro Khanna adds a minor bullish datapoint. Short interest stands at a high 65.2% of tradable volume, indicating elevated bearish positioning. The takeaway: CLSA's bullish initiation adds a fresh vote of confidence at a time when estimates are rising and short interest is elevated, but the stock remains in a largely neutral consensus.

Impact Score

Consensus & Targets

Of 33 analysts covering ADBE, 8 rate it Strong Buy, 9 Buy, 25 Hold, 3 Sell, and 0 Strong Sell. That works out to 52% Buy (17/33), 76% Hold/Sell (25 Hold + 3 Sell = 28/33). The consensus is skewed net-bullish but heavily weighted toward Hold, suggesting broad caution.

Current price: $237.25. Mean target: $272.48 (implied upside +14.8%). Median: $250 (+5.4%). High: $380 (+60.2%). Low: $190 (-19.9%). CLSA's $300 target is above the mean and median, ranking in the upper quartile of analyst targets. The wide spread ($190–$380) reflects deep disagreement on valuation.

Recent Analyst Activity

Over the past 30 days, ADBE has seen 2 upgrades (HSBC from Hold to Buy, and CLSA's initiation) and 0 downgrades. EPS revisions for the current quarter (0q): 30-day revisions up 25, down 0. For the current fiscal year (0y): 30-day revisions up 26, down 0. Estimates are being revised higher across the board, with the current-year EPS consensus rising from $23.56 to $24.42 over 30 days.

Firm Track Record — CLSA

CLSA accuracy: 50% on 16 calls | avg return: 17.7%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

CLSA has a 50% accuracy rate on its 16 rated calls (8 correct, 8 wrong) with an average return of +17.7%. This is a mid-tier record on this stock. The best-performing firms covering ADBE are JP Morgan (100% on 2 calls, avg return +2.9%) and Evercore ISI Group (83% on 6 calls, avg return +4.5%). Worst: RBC Capital (35% on 17 calls, avg return -5.2%) and Oppenheimer (36% on 11 calls, avg return -4.1%). CLSA's record is above average overall but not top-tier.

Earnings Estimates

Cross-Platform Signals

Insider trades: Officer David Ricks bought $1.95M worth on June 25, 2026, a bullish signal. However, CEO Shantanu Narayen executed three sales totaling $18.3M on April 28, 2026. The Ricks buy is a clear bullish contra-signal to the CEO's earlier sales. Congressional activity: Rep. Ro Khanna bought $1k–$15k on June 2, 2026, a minor bullish datapoint. Institutional changes are mixed: Ninety One UK added 38.9% ($55M), while Walleye Capital trimmed 52.8% ($2.8M). Short interest: 2.04M shares short, representing 65.2% of recent trade volume — a very high short ratio that could fuel a squeeze if the bullish thesis gains traction. The Ricks buy and rising estimates converge with CLSA's bullish initiation, while the large CEO sales and high short interest diverge, suggesting elevated risk.

Investment Themes

Documents Analyzed

Report based on filing metadata.

US Market Status